1 / 19

Disease Management in the Private Sector (2002)

Disease Management in the Private Sector (2002). Al Lewis Executive Director Disease Management Purchasing Consortium LLC www.DisMgmt.com. Agenda. Background on Disease Management Purchasing Consortium Size and Growth Pricing and Guarantee Trends

yered
Download Presentation

Disease Management in the Private Sector (2002)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Disease Management in the Private Sector (2002) Al Lewis Executive Director Disease Management Purchasing Consortium LLC www.DisMgmt.com

  2. Agenda • Background on Disease Management Purchasing Consortium • Size and Growth • Pricing and Guarantee Trends • State of the Industry and Impediments to Future Growth • Specifically, employers

  3. Hey, Butch, Who Are These Guys and why are they wasting our precious time? • DMPC membership includes 68 health plans, 4 employers, 4 states, 2 gubernatorial campaigns, 2 states retirement systems and CBO • Does majority of all private sector and Medicaid RFPs (by dollar volume) • As a result, we know most of what goes on in DM

  4. Source of non-employer Disease Management (employers mostly outsourced)

  5. Industry Trends: Market Sizes and Compositions (2001) Total Size: $480MM in fees Asthma 15% Diabetes 10% CHF/Cardio 21% Maternal/Neo 10% Cancer 12% Other 23% ESRD 3% Rare Diseases 4% 4

  6. 2002 is down in # of bidds undertaken

  7. 2002 is down in # bids but up in est. bid size

  8. Disease Management Market Size Estimates($-millions of outsource fees)

  9. Agenda • Background on Disease Management Purchasing Consortium • Size and Growth • Pricing and Guarantee Trends • State of the Industry and Impediments to Future Growth • Specifically, employers

  10. Fee Migration (indexed 1997 to 100—$ fees proprietary)

  11. Guaranteed Savings Deals Guaranteed with LOC or Reinsurance All Consortium Contracts Not Guaranteed Guaranteed No LOC/Reinsurance 1997 1999 2000 1996 2001 To date 1998

  12. Guarantee Migration over time

  13. Agenda • Background on Disease Management Purchasing Consortium • Size and Growth • Pricing and Guarantee Trends • State of the Industry and Impediments to Future Growth • Specifically, employers

  14. State of the Industry • Regulatory Health: Good • Workable HIPAA accommodation • States moving from blocking to facilitating • Economic Health: Good • Companies creating value for shareholders (Accordant sale shows intrinsic value) • Financial Value-Added: Still a Question (clinical/satisfaction value-added not disputed) • Next page

  15. Vendor outcomes have been positive Vendors guarantee savings Few plans drop programs and many add them Financial outcomes metrics not valid They don’t always hit their guaranteed numbers and it’s difficult to reconcile Pressure from employers accounts for that Financial Value-Added: Supporting Arguments

  16. Vendor outcomes aren’t valid Vendors miss their numbers sometimes… …So we can’t be sure of savings No official standard ROI metrics yet Only if you don’t know how to contract with vendors Reinsurance has been purchased 30 times and there have only been 3 claims Fewer things are more certain than guaranteed savings—you can’t lose DM Purchasing Consortium metrics the de facto standard, used in most bids and contracts. Anyone can use them Financial Value-Added: Detractor Arguments

  17. Financial Value-Added • Strong enough evidence to indicate good financial ROI but not strong enough (for Consortium members at least) to do a fee bid—we still like vendors to take risk (though less risk than before) • The tradeoff is higher fees and the strong likelihood of a complex reconciliation (though there are ways to simplify this)

  18. Employer Impediments Same financial issues, plus: • Getting bad advice from consultants • Failure to understand DM-specific biostatistics needed for risk deals • Admission by one consultant at conference that they don’t know how to contract for DM • Using substandard vendors (easy to tell which) • Not knowing when to disintermediate and when to use health plan’s program • Not looking into option of combining with UM/claims-paying

  19. Conclusion • Don’t believe the detractors…but don’t disbelieve them either • DM SHOULD save money… • …but it is not a 100% certain layup so get significant risk in the deal • And make sure of your biostatistics and that your advisor is biostatistically savvy (ask them the same question as a test) and don’t pay them to “reinvent the wheel”—this assistance should cost low five figures

More Related